Ultralight vector dark matter search using data from the KAGRA O3GK run

Among the various candidates for dark matter (DM), ultralight vector DM can be probed by laser interferometric gravitational wave detectors through the measurement of oscillating length changes in the arm cavities. In this context, KAGRA has a unique feature due to differing compositions of its mirrors, enhancing the signal of vector DM in the length change in the auxiliary channels. Here we present the result of a search for U(1)B−L gauge boson DM using the KAGRA data from auxiliary length channels during the first joint observation run together with GEO600. By applying our search pipeline, which takes into account the stochastic nature of ultralight DM, upper bounds on the coupling strength between the U(1)B−L gauge boson and ordinary matter are obtained for a range of DM masses. While our constraints are less stringent than those derived from previous experiments, this study demonstrates the applicability of our method to the lower-mass vector DM search, which is made difficult in this measurement by the short observation time compared to the auto-correlation time scale of DM

Placental Mesenchymal Stem Cells and Extracellular Vesicles on an Extracellular Matrix ImprovedMotor Function Recovery After Acute Spinal Cord Injury

Spinal cord injury (SCI) is a devasting disease with no effective cure. We have shown that placental mesenchymal stromal cells (PMSCs) applied in utero improve ambulatory function in an ovine model of spina bifida and have begun the first-inhuman clinical trial for fetal spina bifida. PMSCs and extracellular vesicles (EVs)have neuroprotective properties and we hypothesized that PMSCs and PMSC-EVs would provide a similar neuroprotective effect in SCI

Marquette Literary Review, Issue 5, Spring 2013

Table of contents Ginger Snaps, Jahnavi Acharya … 3 It is What it is, Benjamin Schmitz … 8 My Friend Cried, Benjamin Schmitz … 9 Sound of an Island, Lara Johann-Reichar, … 10 Cellar Door, Bobby Elliott … 16 Musings, Alexandra Othman … 17 wet., Charlie Mohl … 18 Overcoats, Chrissy Wabiszewski … 19 Hook, Bobby Elliot … 22 All we will ever know Christopher Avallone … 26 A Slice of Life, Kelly Meyerhofer … 27 On, Jahnavi Acharya … 29 Foster’s Mansion, Benjamin Stanley … 30 A Fish, Christopher Avallone … 4

Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021.

Over the past decade, immunotherapy has become an increasingly fundamental modality in the treatment of cancer. The positive impact of immune checkpoint inhibition, especially anti-programmed death (PD)-1/PD-ligand (L)1 blockade, in patients with different cancers has focused attention on the potential for other immunotherapeutic approaches. These include inhibitors of additional immune checkpoints, adoptive cell transfer (ACT), and therapeutic vaccines. Patients with advanced cancers who previously had limited treatment options available may now benefit from immunotherapies that can offer durable responses and improved survival outcomes. However, despite this, a significant proportion of patients fail to respond to immunotherapy, especially those with less immunoresponsive cancer types, and there remains a need for new treatment strategies.The virtual Immunotherapy Bridge (December 1st-2nd, 2021), organized by the Fondazione Melanoma Onlus, Naples, Italy in collaboration with the Society for Immunotherapy of Cancer addressed several areas of current research in immunotherapy, including lessons learned from cell therapies, drivers of immune response, and trends in immunotherapy across different cancers, and these are summarised here

Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)

Abstract The discovery and development of novel treatments that harness the patient’s immune system and prevent immune escape has dramatically improved outcomes for patients across cancer types. However, not all patients respond to immunotherapy, acquired resistance remains a challenge, and responses are poor in certain tumors which are considered to be immunologically cold. This has led to the need for new immunotherapy-based approaches, including adoptive cell transfer (ACT), therapeutic vaccines, and novel immune checkpoint inhibitors. These new approaches are focused on patients with an inadequate response to current treatments, with emerging evidence of improved responses in various cancers with new immunotherapy agents, often in combinations with existing agents. The use of cell therapies, drivers of immune response, and trends in immunotherapy were the focus of the Immunotherapy Bridge (November 30th–December 1st, 2022), organized by the Fondazione Melanoma Onlus, Naples, Italy, in collaboration with the Society for Immunotherapy of Cancer